IMR Press / FBL / Volume 9 / Issue 1 / DOI: 10.2741/1276

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Prospects for neuroprotection in multiple sclerosis
Show Less
1 Departments of Oncology & Clinical Neurosciences, The University of Calgary, 3330 Hospital Drive N.W., Calgary, Alberta T2N 4N1, Canada
Front. Biosci. (Landmark Ed) 2004, 9(1), 864–872;
Published: 1 January 2004

Axonal injury and neuronal loss are now recognised to be hallmarks of multiple sclerosis (MS) in addition to neuroinflammation and demyelination. This review discusses the factors that contribute to neural degeneration, and it emphasizes the need to confer neuroprotection in MS. The beneficial role of neuroinflammation is highlighted, and the possibility that glatiramer acetate enables neuroprotection in MS through beneficial inflammation is evaluated. Finally, the prospect of an experimental treatment, minocycline, in producing neuroprotection in MS is suggested.

Nervous system
Glatiramer Acetate
Multiple sclerosis
Back to top